Press Releases

WASHINGTON, D.C., July 24, 2017 – The Alliance for Regenerative Medicine (ARM) today announced the publication of its reimbursement and market-access focused white paper, “New Payment and Financing Models for Curative Regenerative Medicines,” available online today in In Vivo.

WASHINGTON, DC, July 19, 2017 – The Alliance for Regenerative Medicine (ARM) today announced the initial slate of companies selected to present at its upcoming Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017.

Over the course of the three-day conference, more than 850 are expected to attend, including executives from leading companies, venture capital and institutional investors, tools and development platform providers, clinicians, patients and patient advocates, life-science media and more.

WASHINGTON, DC, July 12, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, has issued the following statement in response to today’s U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee meeting discussing Novartis’ biologics license application for tisagenlecleucel, the company’s anti-CD19 CAR-T product for the treatment of pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL):

WASHINGTON, DC, June 27, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, formally announces that its Board of Directors has named Janet Lynch Lambert as the organization’s first chief executive officer. The organization informed its membership early last week of the decision.

WASHINGTON, DC, May 11, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, announced the speaker line up for its eighth Annual Dinner and Legislative Fly-In, to be held May 23 and 24 in Washington, D.C. This event honors recent accomplishments in the sector and enables ARM members to advocate on Capitol Hill for legislative support of gene and cellular therapies and other regenerative medicines.

WASHINGTON, D.C., May 9, 2017 – The Alliance for Regenerative Medicine (ARM) today released the agenda for the inaugural Cell & Gene Exchange, the only partnering conference that brings together the regulatory, business and patient advocacy communities across the cell and gene therapy sectors. Co-produced by ARM and EBD Group and held in partnership with Global Genes, the event will take place May 22 and 23 in Washington, D.C.

WASHINGTON, DC- April 6, 2017 -  The Alliance for Regenerative Medicine (ARM) today released the complete agenda for its upcoming fifth annual Cell & Gene Therapy Investor Day, taking place April 27, 2017 in Boston, MA. This event, co-hosted by Piper Jaffray and held in partnership with Cowen and Company is the only investor conference specifically focused on cell and gene therapies, offering exclusive access to the field's most promising companies.

BRUSSELS, Belgium and WASHINGTON, D.C. – March 16, 2017 – The Alliance for Regenerative Medicine (ARM), the international advocacy organisation representing the cell and gene therapy and broader regenerative medicine sector, has taken note of the Letter from the Pharmaceutical Inspection Co-operation Scheme (PIC/S) to the European Commission stating their opposition, for public health reasons, to the publication of the Guidelines on Good Manufacturing Practice (GMP) for Advanced Therapy Medicinal Products (ATMPs) as a stand-alone document.

WASHINGTON, DC – March 13, 2017 – The Alliance for Regenerative Medicine (ARM) today issued the following statements on the Trump Administration’s nomination of Scott Gottlieb, M.D., as commissioner of the U.S. Food and Drug Administration (FDA).

WASHINGTON, D.C. – March 7, 2017 – The Alliance for Regenerative Medicine (ARM) today announced the release of its 2016 annual data report, offering an in-depth look at trends and metrics for the cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector.

Pages